COSMO PHARMACEUT. EO-,26/ NL0011832936 /
| 2024-11-06 5:35:35 PM | Chg. -0.50 | Volume | Bid2024-11-06 | Ask2024-11-06 | Market Capitalization | Dividend Y. | P/E Ratio |
|---|---|---|---|---|---|---|---|
| 69.00EUR | -0.72% | 218 Turnover: 15,265 |
-Bid Size: - | -Ask Size: - | 1.12 bill.EUR | 2.90% | 971.24 |
Assets
| 2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Property and Equipment | 20.7000 | 30.2000 | 28.6000 | 30.2000 | 29.3000 | ||||||
| Intangible Assets | 19.5000 | 28.5000 | 35.5000 | 49.2000 | 26.6000 | ||||||
| Long-Term Investments | 72 | 93.8000 | 41.9000 | 53.9000 | 114.5000 | ||||||
| Fixed Assets | 256.4000 | 300.7000 | 251.5000 | 282.8000 | 343.3000 | ||||||
| Inventories | 2.3000 | 3.2000 | 3.9000 | 6.1000 | 5.7000 | ||||||
| Accounts Receivable | 15 | 13.2000 | 12.8000 | 16.5000 | 23 | ||||||
| Cash and Cash Equivalents | 117.6000 | 144.9000 | 210.7000 | 110.4000 | 185.9000 | ||||||
| Current Assets | 187.1000 | 197.3000 | 374.2000 | 302.4000 | 252.9000 | ||||||
| Total Assets | 443.5000 | 498 | 625.7000 | 585.2000 | 596.2000 | ||||||
Liabilities
| 2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Accounts Payable | 6.1000 | 11.3000 | 8.8000 | 7.8000 | 8.4000 | ||||||
| Long-term debt | 4.5000 | 3.8000 | 157.6000 | 163.3000 | 165.2000 | ||||||
| Liabilities to Banks | 5.3000 | 4.4000 | 158.1000 | 164.8000 | 168.1000 | ||||||
| Provisions | 4.3000 | 4.3000 | 7.5000 | 8.8000 | 6.3000 | ||||||
| Liabilities | 27.9000 | 27.9000 | 180.8000 | 191.4000 | 196 | ||||||
| Share Capital | 3.7000 | 3.9000 | 3.9000 | 3.9000 | 3.9100 | ||||||
| Total Equity | 415.5000 | 470.1000 | 444.9000 | 393.7000 | 400.1000 | ||||||
| Minority Interests | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Total liabilities equity | 443.5000 | 498 | 625.7000 | 585.2000 | 596.2000 | ||||||
Income Statement
| 2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | 67.7000 | 67.2000 | 65.6000 | 62.5000 | 60.9000 | ||||||
| Depreciation (total) | - | - | - | - | - | ||||||
| Operating Result | 21 | -15.5000 | -16.6000 | -12.3000 | 6.9000 | ||||||
| Interest Income | - | - | - | - | - | ||||||
| Income Before Taxes | 27.5000 | -32.4000 | -17.5000 | -21.2200 | -6.9000 | ||||||
| Income Taxes | -8.2000 | 0.0000 | -.6000 | -3.2000 | -1 | ||||||
| Minority Interests Profit | 0.0000 | 0.0000 | 0.0000 | 0.0000 | 0.0000 | ||||||
| Net Income | 19.3000 | -32.4000 | -18 | -24.4000 | -7.9000 | ||||||
Per Share
Cash Flow
| 2016 IFRS in mill. EUR |
2017 IFRS in mill. EUR |
2018 IFRS in mill. EUR |
2019 IFRS in mill. EUR |
2020 IFRS in mill. EUR |
|||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash Flow from Operating Activities | 26.4000 | -10 | -16.2000 | -17.6000 | 10.1000 | ||||||
| Cash Flow from Investing Activities | 40.2000 | -22.3000 | -71.8000 | -48.7000 | 75.4000 | ||||||
| Cash Flow from Financing | -22.6000 | 72.7000 | 144.4000 | -34.5000 | -11.9000 | ||||||
| Decrease / Increase in Cash | 46.4000 | 40.4000 | 62.4000 | -102 | 76.5000 | ||||||
| Employees | 217 | 301 | 306 | 234 | 265 | ||||||
